A Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (PAH) in India (MK-7962-037)

Researchers are looking for other ways to treat people in India with pulmonary arterial hypertension (PAH), also known as Group 1 pulmonary hypertension (PH). In PAH, the blood vessels in the lungs become thick and narrow, which makes it harder for blood to flow to the lungs. This causes high blood pressure in the lungs and can overwork the heart. PAH can make it hard to breathe and be active. Researchers want to learn if sotatercept, the study medicine, can be given with standard treatment to help treat PAH. The standard treatment (the usual treatment) for PAH includes one or multiple medicines. However, these may not fully work or treat the symptoms of PAH in some people. The goal of this study is to learn about the safety and tolerability of sotatercept when it is given with standard treatment to people in India.

NCT Number	NCT07600723
Lead Sponsor	Merck Sharp & Dohme LLC
Conditions	Pulmonary Arterial Hypertension
Enrollment	30 participants
Start Date	2026-11-04
Primary Completion	2028-04-03 (estimated)
Study Completion	2028-04-03 (estimated)
Updated on ClinicalTrials.gov	2026-08-07